Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04950504 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
A Phase 1 study, sponsored by COUR Pharmaceutical Development Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04950504: Clinical Trial Phase 1 study, sponsored by COUR Pharmaceutical Development Company.
NCT04950504 is a Phase 1 study that was terminated before completion, run by COUR Pharmaceutical Development Company. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04950504, a Phase 1 study, was terminated before completion, sponsored by COUR Pharmaceutical Development Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects in Part B.
Primary Outcome
Frequency tables will be presented by treatment group for all AEs and SAEs by System Organ Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by treatment group for AEs leading to discontinuation from TP and study, by severity, and by causality. No formal statistical testing will be done.
Interventions
- DRUG Placebo
- DRUG CNP-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 1 |
Why NCT04950504 stopped before completion
NCT04950504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04950504 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04950504 about?
NCT04950504 is a clinical study titled "Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy". This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to b...
What is the current status of trial NCT04950504?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-06-02. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT04950504?
The interventions under investigation include: Placebo (DRUG), CNP-201 (DRUG).
Who is sponsoring clinical trial NCT04950504?
This trial is sponsored by COUR Pharmaceutical Development Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04950504's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI